- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Gliclazide - Revisiting a Preferred Sulphonylurea in 2025 - Dr Silima Tarenia and Dr Shehzad Ruman - Video
Overview
On this World Diabetes Day, we bring you a special episode of Dia Dialogues titled "Gliclazide - Revisiting a Preferred Sulphonylurea in 2025."
In this discussion, Dr Silima Tarenia, Endocrinologist from Kolkata, and Dr Shehzad Ruman, Endocrinologist from Hyderabad, share their expert insights on the evolving role of modern sulphonylureas (SUs) in type 2 diabetes (T2D) management.
Modern SUs have long been trusted for their reliable glucose control, and among them, Gliclazide stands out for its proven efficacy, safety, and patient-centric benefits.
As diabetes care advances in 2025, understanding what makes Gliclazide unique among other therapies and SUs is vital for clinical decision-making.
They give their insights on:
1) The place of modern SUs in the evolving T2D care continuum in 2025
2) The unique clinical advantages that make Gliclazide a preferred choice in T2D management




